z-logo
open-access-imgOpen Access
Development of three ecological spectroscopic methods for analysis of betrixaban either alone or in mixture with lercanidipine: greenness assessment
Author(s) -
Amal A. El-Masry,
Dalia R. ElWasseef,
Manal Eid,
Ihsan A. Shehata,
Abdallah M. Zeid
Publication year - 2022
Publication title -
royal society open science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.84
H-Index - 51
ISSN - 2054-5703
DOI - 10.1098/rsos.211457
Subject(s) - lercanidipine , environmental science , ecology , biochemical engineering , computer science , biology , engineering , blood pressure , endocrinology
Three eco-friendly spectrophotometric methods were developed for determination of the novel anticoagulant drug, betrixaban (BTX). The first method (method A) was based on direct analysis of BTX at 229.4 nm on the zero-order spectrum using methanol as the optimum solvent. While the second method (method B) was based on measuring difference absorption value (ΔA) of BTX at 335 nm, which was obtained from pH-induced spectral difference (difference spectra of BTX in 0.1 M NaOH versus 0.1 M HCl). The third method (method C) was based on measurement of the first-derivative amplitudes of BTX and its co-administered Ca channel blocker lercanidipine (LER) at 304 and 229 nm for simultaneous assay of BTX and LER, respectively. All methods were linear over concentration ranges of 1.0–20.0 and 8.0–80.0 µg ml−1 for BTX in methods A and B, respectively, and of 1.0–20.0 and 1.0–25.0 µg ml−1 for BTX and LER, respectively, in method C. The three methods were fully validated and assessed for greenness by three metrics: analytical eco-scale, green analytical procedure index and Analytical GREEnness metrics. The results indicated the validity and greenness of the proposed methods. Moreover, the methods were applied to assay the studied analytes in their dosage forms with high percentage of recovery and low percentage of relative s.d. values.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here